Impact of convalescent plasma therapy for treatment of Covid-19
Keywords:
Coronavirus, immunization, pandemic, emergencies, convalescent plasmaAbstract
Coronavirus SARS-CoV-2 is a leading cause of public health emergencies, particularly, has only few literatures have summarized its clinical and radiologic pattern, however the treatment strategies are confined, whilst it is not just medical, economic and social but also has documented emphasis. Furthermore, the former Chinese guideline has highlighted that convalescent plasma (CP) therapy was a promising treatment for alarming Covid-19. CP is a pattern of passive immunization. Usually, CP was notoriously used to enhance the survival speed in a diverse outbreak such as SARS, MERS, influenza, Ebola virus disease, etc. It predominantly acts by neutralizing antibodies that significantly bind to the specific antigens of SARS-CoV therein protecting the susceptibility of individuals, moreover, urgently needed to reduce the immediate health hazard in this Covid-19 pandemic scenario. On the other hand, CP therapy is predominantly efficacious at the initial stage of disease ultimately confirmed by various research literature. This short review highlights on the use, historical context and its benefits in treatment of Covid-19.
References
Winau F, Winu R. Emil von Behring and serum therapy. Microbes Infect 4:185-188, 2002.
Shakir EM, Cheung DS, Grayson MH. Mechanisms of immunotherapy: historical perspective. Ann Allergy Asthma Immunol 105:340-347, 2010.
Gillespie TR, Leendertz FH. COVID‐19: protect great apes during human pandemics. Nature 579(7800):497, 2020.
Jacobsen KH. Will COVID‐19 generate global preparedness? Lancet 395:1013‐1014, 2020
Banerjee A, Kulcsar K, Misra V, Frieman M, & Mossman K. Bats and Coronaviruses. Viruses 11:41, 2019.
Schoeman D & Fielding BC. Coronavirus envelope protein: current knowledge. Virology J 16:69, 2019.
M. Wang et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269-271, 2020.
World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID‐19 disease is suspected. Interim guidance 13 March 2020.
Rajendran K, Narayanasamy K, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review. J Med Virol 92:1475-1483, 2020.
Wong HK, Lee CK. Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sang 115:545-547, 2020.
Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, Al-Omari A, Al-Hameed F, Hayden FG. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis 22:1554, 2016.
Y. Cheng et al, Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 24:44-46, 2005.
B. Zhou, N. Zhong, Y. Guan. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357:1450-1451, 2007.
Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020.
L. Shang,J. Zhao, Y. Hu, R. Du, B. Cao, On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 395, 683-684, 2020.
Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 10: 676-678, 2004.
Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med 38 (4 suppl):e66–e73, 2010.
Luke TC, Kilbane EM, Jackson JL, & Hoffman SL. Meta-Analysis: Convalescent Blood Products for Spanish Influenza Pneumonia: A Future H5N1 Treatment? Annals Intern Med 145(8):599-609, 2006.
Chan JF, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes & Infect 9:221-236, 2020.
Walls AC, et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181(2):281-292 e286, 2020.
Racine R & Winslow GM. IgM in microbial infections: taken for granted? Immunol letters 125(2):79-85, 2009.
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 130:1545-1548, 2020.
Kai Duan et al. The feasibility of convalescent plasma therapy in severe COVID19 patients: a pilot study. medRxiv 2020.03.16.20036145.
Downloads
Published
Issue
Section
License
Authors who publish with the American Journal of Experimental and Clinical Resaerch (AJECR) agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
